PALATIN TECHNOLOGIES INC (PTN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$12.66-0.16%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Palatin aims to grow revenue from $8.83M in 2026-Q3. Losses narrowed from $7.3M to $1.58M recently. The company has new partnerships and a Nasdaq listing plan.
Revenue is expected to fall 33% next year. Cash flow is negative and losses remain. The stock is down 51% from its high.
The market expects about 33% revenue decline next year. Our fair value is near $41, reflecting a turnaround but risks remain.
Breaks if: cash from operations worsens beyond -$5 million in 2026-Q3
Focus on controlling negative cash from operations and reducing operating losses over time.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The business shows volatility in management and earnings, which adds risk, but the sector is currently favorable, providing potential support for growth.
The current valuation suggests that the market views PTN as cheap compared to its peers. However, there is a notable expectations gap, indicating that investors are not fully pricing in the risks associated with the company's fragile earnings quality.
Management has prioritized increasing revenue and improving profitability, but recent cash flow remains negative, indicating mixed progress. The recent financial performance has been neutral, with some volatility in earnings that could affect future results.
The long-term thesis hinges on several factors, including management's ability to execute on their priorities and the overall health of the healthcare sector. Additionally, any negative guidance or worsening economic indicators could significantly impact performance.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Cash from operating activities remained negative, with -$1.6M in 2026-Q1 worsening to -$4.8M in 2026-Q2 and -$4.4M in 2026-Q3. Operating losses narrowed in recent quarters, indicating some cost control but cash flow remains negative, showing limited progress.
“Cash from operations was -$4.4M”
“Cash from operations was -$4.8M”
“Cash from operations was -$1.6M”
Breaks if: listing transfer not completed by end 2026-Q3
Voluntarily withdraw listing from NYSE American and transfer common stock listing to Nasdaq Capital Market.
Newly stated in 2026-Q3. Management announced the intent to voluntarily withdraw the listing from NYSE American and transfer to Nasdaq Capital Market. This is a one-time regulatory event with no financial metrics to track progress in the data.
“Notice to NYSE American to withdraw listing and transfer to Nasdaq Capital Market”
Breaks if: operating loss worsens beyond -$2 million in 2026-Q3
Focus on growing revenue from low levels and improving operating income and net income over time.
Stated as a priority in 3 of last 3 quarters. Revenue was $8.83M in 2026-Q1 and 2026-Q3 but dropped to $116K in 2026-Q2. Operating income improved from a loss of $7.3M in 2026-Q2 to a loss of $1.58M in 2026-Q3. The trajectory shows some volatility but recent quarters indicate progress toward improving profitability.
“Revenue was $8.83M with operating loss of $1.58M”
“Revenue was $116K with operating loss of $7.3M”
“Revenue was $8.83M with operating income of $4.66M”
Breaks if: revenue falls below $8 million in 2026-Q3
Focus on growing revenue from low levels and improving operating income and net income over time.
Stated as a priority in 3 of last 3 quarters. Revenue was $8.83M in 2026-Q1 and 2026-Q3 but dropped to $116K in 2026-Q2. Operating income improved from a loss of $7.3M in 2026-Q2 to a loss of $1.58M in 2026-Q3. The trajectory shows some volatility but recent quarters indicate progress toward improving profitability.
“Revenue was $8.83M with operating loss of $1.58M”
“Revenue was $116K with operating loss of $7.3M”
“Revenue was $8.83M with operating income of $4.66M”
Over the next 1 to 3 years, PTN's prospects will depend on its management execution and sector dynamics. Not investment advice.